Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow
microenvironment, resulting in apoptosis and inhibition of cell-cycle progression …

Background Multiple myeloma is a malignancy of plasma cells accounting for approximately
1% of cancers and 12% of haematological malignancies. The first‐in‐class proteasome …

Influenza virus exploits a number of cellular signaling pathways during the course of its
replication, rendering them potential targets for new therapeutic interventions. Several …

This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide,
and lenalidomide in patients with multiple myeloma. We searched the Medline, Scopus, and …

Background Several targeted therapies for cancer have been associated with
cardiovascular toxicity. The evidence for this association has not been synthesized …

This study characterized the costs of multiple myeloma (MM) during first-line (1L), second-
line (2L) and third-line (3L) treatment from the US payer perspective. Patients with≥ 2 …

Plasma cells play a crucial role for the humoral immune response as they represent the
body's factories for antibody production. The differentiation from a B cell into a plasma cell is …

Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for
adapting to their rapid growth. These changes include using aerobic glycolysis, lipid …

The maximum tolerated dose (MTD) of quisinostat+ bortezomib+ dexamethasone in patients
with relapsed multiple myeloma was evaluated in a phase-1b, open-label, multicenter,'3+ …

This study aimed at comparing bortezomib, thalidomide, and lenalidomide in patients with
multiple myeloma (MM) for safety and efficacy using meta-analysis. This meta-analysis …